ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Venture capitalists increased their investment in biotechnology start-up firms in the third quarter, but the increase masked a downward trend in biotech investing. Although investment in the sector rose 64% to $1.2 billion compared with the second quarter, the increase was the result of a large number of follow-on investments, according to the MoneyTree investment report compiled by PricewaterhouseCoopers and the National Venture Capital Association, which used data from Thomson Reuters. The number of first-time biotech deals was just 15 in the third quarter, down from 17 in the previous two quarters and 28 in the fourth quarter of 2011. Clean technology sector investments were $791 million in the quarter, compared with around $1 billion in the previous three quarters.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter